XOMA Corp  

(Public, NASDAQ:XOMA)   Watch this stock  
Find more results for XOMA
3.69
-0.14 (-3.66%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.61 - 3.81
52 week 3.22 - 9.57
Open 3.80
Vol / Avg. 1.34M/2.06M
Mkt cap 443.87M
P/E     -
Div/yield     -
EPS -0.84
Shares 115.47M
Beta 3.04
Inst. own 77%
Mar 11, 2015
Q4 2014 XOMA Corp Earnings Call - 4:30PM EDT - Add to calendar
Mar 11, 2015
Q4 2014 XOMA Corp Earnings Release - 4:00PM EDT - Add to calendar
Mar 9, 2015
XOMA Corp at ROTH Conference - 3:00PM EDT - Add to calendar
Mar 4, 2015
XOMA Corp at Cowen Health Care Conference - 10:40AM EST - Add to calendar
Feb 24, 2015
XOMA Corp at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -280.35% -349.94%
Operating margin -398.23% -164.18%
EBITD margin - -155.08%
Return on average assets -71.81% -103.18%
Return on average equity - -1419.43%
Employees 180 -
CDP Score - -

Address

2910 SEVENTH ST
BERKELEY, CA 94710
United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company�s lead product candidate, gevokizumab, is a proprietary potent, fully humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta. The Company initiated three Phase III clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis. It is also are conducting a trial of gevokizumab in pyoderma gangrenosum (PG), a rare ulcerative skin disease. It also has an active gevokizumab Proof-of-Concept (POC) development program to identify indications for pivotal development. XOMA 3AB is a multi-antibody product designed to neutralize the most potent of the botulinum toxins, Type A, which causes paralysis and is a bioterrorism threat.

Officers and directors

W. Denman Van Ness Lead Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
John W. Varian Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Frederick Kurland Chief Financial Officer, Vice President - Finance, Secretary
Age: 63
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 66
Bio & Compensation  - Reuters
Paul D. Rubin M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Tom Klein Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Kelvin M. Neu M.D. Director
Age: 41
Bio & Compensation  - Reuters
William K. Bowes Jr Independent Director
Age: 79
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 80
Bio & Compensation  - Reuters
Joseph M. Limber Independent Director
Age: 61
Bio & Compensation  - Reuters